StockWatch
·

Concord Drugs Ltd Q3 FY26 Results

CONCORDQ3 FY26 Results
Filing
MetricValue ( Cr)Q2 FY26Q3 FY25
Revenue16.9729.0%57.1%
Total Income16.9928.9%57.3%
Expenditure16.6928.8%62.5%
PBT0.3031.0%43.8%
Net Profit0.2230.0%4.4%
OPM5.43%3.42pp8.58pp
NPM1.28%0.02pp0.82pp
EPS0.1648.4%30.4%
View full financials

Informational and educational content only. Not investment advice.